Navigation Links
Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2010 Unaudited Financial Results on Tuesday, March 8, 2011
Date:2/24/2011

NANJING, China, Feb. 24, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2010 on Tuesday, March 8, 2011, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Tuesday, March 8 at 9 p.m. Beijing/Hong Kong time).To access the conference call, please dial:United States toll-free:

+1.866.831.5605International:

+1.617.213.8851China Telecom:

10.800.130.0399 / 10.800.120.2655 / 10.800.152.1490China Netcom:

10.800.852.1490 / 10.800.712.2655China 400 (for mobile users)

400.881.1630 / 400.881.1629Hong Kong:

+852.3002.1672Please ask to be connected to Q4 2010 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 56440566

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:

+1.888.286.8010 International:

+1.617.801.6888The passcode for replay participants is: 22405893.The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:
Email: ir@simcere.comIn Nanjing:

Yehong Zhang
President
Simcere Pharmaceutical Group
Tel: 86-25-8556-6666 ext 8811In the United States:

Kate Tellier
Brunswick Group
Tel: 1-212-333-3810In Beijing:
Ruirui Jiang
Brunswick Group
Tel: 86-10-5960-8600In Hong Kong:
Joseph Lo Chi-Lun
Brunswick Group
Tel: 852-3512-5000
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Appoints Industry Veteran Mr. Hong Zhao as Executive Vice President of Sales and Marketing
2. Simcere Pharmaceutical Group Announces Resignation of CFO Frank Zhao
3. Simcere Pharmaceutical Group to Announce Third Quarter 2010 Financial Results on Thursday, November 11, 2010
4. Simcere Pharmaceutical Group to Announce Second Quarter 2010 Financial Results on Thursday, August 12, 2010
5. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
6. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
7. Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2010 Results
8. Simceres Diosmectite API Passes EU-GMP Inspection
9. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
10. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
11. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide ... achieve significant growth as next generation systems provide ... use radiology for cancer surgery. New systems pinpoint ... overdosing that has been such a problem previously, ... delivered. Radiosurgery robots take cancer surgery far beyond ...
(Date:2/4/2016)... , Feb. 4, 2016  Montoya Love is recognized ... the field of Pharmaceuticals. Montoya is the Regulatory Systems ... Manufacturing and selling ... Becton Dickinson provides healthcare institutions, clinical laboratories and ... fifty countries across the globe. ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 2016 , ... Love is in the air at King Kullen! The local ... packaging. This staple for Valentine’s Day is a must-have, and can be picked up ... not only are long-stem roses available, but also other flower bouquets, elegantly wrapped and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV show, hosted ... feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream on Friday, ... on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors - people ...
(Date:2/5/2016)... ... 2016 , ... The event is being held on April 7, 2016 from ... Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and cure ... disease and is the architect of this informative event to raise awareness and funds ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, MD and Heather ... Napa Valley office. The technique utilizes the body’s own healing abilities to quickly ... Furnas, are part of only a select few cosmetic surgeons bringing this procedure ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... College President George H. Van Allen have signed a joint enrollment and degree ... a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The ...
Breaking Medicine News(10 mins):